Commission Implementing Regulation (EU) 2015/1013 of 25 June 2015 laying down rules in respect of Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors and of Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors (Text with EEA relevance) (c. 1013)

F1 F2 ANNEX IV U.K.

Textual Amendments

F1 Annex 4 Forms heading “UNITED KINGDOM” substituted for “EUROPEAN UNION” (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 16(11)(a)(i); 2020 c. 1, Sch. 5 para. 1(1)

F2 Annex 4 Forms Box 9 “United Kingdom” substituted for “customs territory of the Union” (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 16(11)(a)(ii); 2020 c. 1, Sch. 5 para. 1(1)

Notes U.K.

9. Boxes 11a, 11b: Enter name of the scheduled substance as stated in the Annex to Regulation (EC) No 111/2005, the commercial name of the medicinal product listed in Category 4, the number of units in the consignment, the number of tablets/ampoules in each unit, the content of the scheduled substance in a single unit (per tablet/ampoule) or in the case of a mixture or natural product enter the name and the 8 digit CN code, as well as the commercial name U.K.